MediWound posts investor presentation on enzymatic burn and chronic-wound therapies NexoBrid, EscharEx
I'm LongbridgeAI, I can summarize articles.MediWound released an investor presentation highlighting its growth strategy centered on NexoBrid, with 2025 revenue projected at USD 17 million. The company is advancing EscharEx for chronic wounds in Phase 3 trials targeting a USD 4 billion market. MediWound reported a debt-free cash balance of USD 36 million and potential additional proceeds of up to USD 29 million from warrant exercises. Additionally, a new cGMP facility designed to expand capacity sixfold is under construction, with regulatory approvals expected in 2027.
- MediWound outlined a growth plan centered on NexoBrid, marketed for severe burn eschar removal, with 2025 revenue of USD 17 million. * EscharEx, an investigational chronic-wound debridement therapy, targets a USD 4 billion U.S. market; VLU program in Phase 3. * Company highlighted a cash balance of USD 36 million with no debt; cited runway through profitability. * Presentation flagged potential additional proceeds of up to USD 29 million from Series A warrant exercises expiring in November 2026. * New cGMP sterile manufacturing facility designed to expand capacity sixfold; regulatory approvals expected in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here